Print PDF

Sheppard Mullin Adds Corporate Partner in Del Mar


Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Edwin Astudillo has joined the firm as a partner in the Corporate and Securities practice based in the firm’s San Diego (Del Mar) office. He was most recently co-managing partner of Breakwater Law Group, LLP in San Diego, a firm he co-founded in 2016.  Astudillo was previously an associate at Sheppard Mullin from 2008 to 2013.

“Edwin’s significant public company clients and experience are great fits for our corporate practice.  In addition, his familiarity with the issues that life sciences companies face builds on our life sciences practice which continues to be a priority for us.  Edwin also expands our securities law capacity and brings additional public company mergers and acquisitions expertise to the group.  Welcome back, Edwin!” said Jon Newby, Sheppard Mullin’s vice chairman.

Commenting on Astudillo’s addition, Jeralin Cardoso, Practice Group Leader of the firm’s Corporate and Securities Practice Group, said, “It’s great to have Edwin back at Sheppard Mullin.  Our corporate practice generally and our public company and capital markets practices specifically had a very active 2021 and we expect 2022 to be even busier.  Edwin’s return certainly strengthens our capabilities.”

Astudillo has deep experience in public company reporting, securities offerings, corporate governance, and public and private mergers and acquisitions.  He has represented numerous public companies in those matters and in a variety of projects that flow from such representation.  In addition to his busy practice, Astudillo previously served as co-vice chair for Legislation on the Corporations Committee of the California State Bar.  He received his B.S., with honors, from California Lutheran University and his J.D. from Pepperdine School of Law. 

About Sheppard Mullin’s Corporate and Securities Practice 

One of the firm's core strengths, Sheppard Mullin’s Corporate and Securities practice group assists clients throughout the United States and abroad in maximizing their business opportunities. We represent clients that range from private to public companies and from startups and emerging businesses to international corporations. We are proud to offer CRADLE TO LIQUIDITY® services.  We provide general business legal advice, assist in structuring and implementing major transactions, prepare agreements to address unique business arrangements and consult with clients to resolve major business and ownership issues. We handle such matters as initial and later stage venture and other financings; leveraged buyouts and recapitalizations; public offerings; mergers and acquisitions; SEC compliance; private equity transactions; real estate capital markets transactions; corporate, LLC and partnership formation; and corporate partnering, joint venture and other strategic alliance arrangements. Because of our diverse client base, we have experience representing substantial entities in complicated multinational and multi-state transactions, as well as advising smaller and emerging clients on the full spectrum of business matters.

About Sheppard Mullin’s Life Sciences Industry Team

Sheppard Mullin assists clients in the life sciences industry with strategic issues that range from acquisitions to antitrust, entity formation to enforcement and investigations, incorporations to IPOs, licensing to litigation, patents to product liability, and trademarks to transactions. In an industry where partnerships and collaborations are on the rise and there is pressure to produce results, we work hand-in-hand with our clients in their drive for success and profitability.  Our Life Sciences team is comprised of a cross-section of attorneys, patent agents, and scientific advisors whose particular strengths cover the legal needs of both emerging and established companies. Many of our team members have hands-on research experience and advanced degrees, including Ph.D.s in the areas of biochemistry, cell biology, chemistry, molecular biology, bioinformatics, pharmacology, and bio-medical engineering enabling us to fully understand our clients' business and objectives.


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.